FDA Approves Lucentis to Treat Diabetic Macular Edema

For many people who have experienced diabetic macular edema (DME), the future looks a little clearer. On August 10, 2012, the U.S. Food and Drug Administration (FDA) approved use of the drug Lucentis for the treatment of DME. Developed by Genentech, Lucentis is the first and only FDA-approved medicine for the condition. Diabetic macular edema […]

JDRF Discusses New Treatment for Diabetic Eye Disease

Developing effective treatments for diabetic retinopathy is a key part of JDRF’s research goals. Until recently, the only treatment for diabetic macular edema was with lasers that often halted the worsening of the condition but did not improve a person’s eyesight. Now, however, a promising new treatment has emerged in the form of a drug called Lucentis (known generically as ranibizumab).

JDRF Funds Testing of New Drug for Diabetic Macular Edema

In one of the largest studies of its kind, JDRF has partnered with iCo Therapeutics to investigate a potential new drug that could, if successful, broaden treatment options for people living with DME. The Phase II trial, led and coordinated by Johns Hopkins University investigators, is currently recruiting participants. To inquire about participation, please contact Dr. Quan Dong Nguyen or click here.

Lucentis for Diabetic Eye Disease

Genentech, Inc., a member of the Roche Group, announced that its second Phase III study known as RISE, which is evaluating the drug Lucentis in patients with diabetic macular edema, met its primary clinical endpoint. Results showed that after 24 months, a significantly higher percentage of patients receiving monthly injections of Lucentis experienced improved vision […]

August Update

On August 3, JDRF, in collaboration with The Leona M. and Harry B. Helmsley Charitable Trust, announced the award of a $4.6 million grant to the laboratory of Camillo Ricordi, M.D., of the Diabetes Research Institute at the University of Miami. The three-year grant will fund research in the area of beta cell encapsulation, a […]

Eye Disease Treatment Shown Effective

A groundbreaking study has identified the first new treatment for people with diabetic eye disease in the last 25 years. The results show it not only stops the progress of eye disease, but improves vision – a huge improvement over any other treatment now available. The study, a Phase II clinical trial, showed that the […]

Lucentis Treatment Shown Effective Against Eye Disease

The two-year study compared Lucentis plus laser therapy to laser therapy alone for people with diabetic macular edema (DME), a major complication of diabetes that can result in vision loss. Half of the people treated with the Lucentis therapy showed improvement in their vision – results that were about twice as good as laser treatment alone.

JDRF’s Relationship with Genentech Helps Support Eyesight-Saving Drug

The collaborative relationship between JDRF and Genentech contributed vital information about the performance of this drug, which can provide an immediate treatment for a serious diabetes-related complication that affects adults living with type 1 diabetes. We are pleased to see the European approval of Lucentis, a first-time treatment for diabetes-related eye disease, and JDRF continues to advocate for the approval of Lucentis in the United States.